Use of omeprazole at a Basic Health Unit in southern Brazil: patient profile, indication, and duration of use
DOI:
https://doi.org/10.5712/rbmfc11(38)1153Keywords:
Omeprazole, Drug Prescriptions, Health CentersAbstract
Introduction: Proton pump inhibitors (PPIs) are one of the most prescribed therapeutic classes worldwide. Omeprazole, a PPI, is included in the essential medicines list. Studies indicate that short-term use of PPIs can be safe, but that their long-term use is associated with adverse effects. Objective: To evaluate the profile of patients prescribed omeprazole at a Basic Health Unit (BHU) and to evaluate the duration of use, prescribed dose, and indication for use. Methods: This was a cross-sectional study. The medical records of patients prescribed omeprazole in May 2014 were identified by the pharmacy of the BHU, and were reviewed. Results: Of the 349 patients included, 75.4% were female patients and the average age was 64.6 years. The average number of drugs prescribed was 4.5 per patient. A dose of 20 mg was prescribed most frequently (69.8%), and 84.3% of patients had been prescribed omeprazole for more than six months. Gastro-esophageal reflux disease and gastric ulcers were the most cited indications for use. However, in 29.5% of the patients in the medical records examined, no indication for the use of omeprazole could be found. Conclusion: Older age and the number of prescription drugs were associated with increased omeprazole use. These factors can also be associated with irrational, and sometimes unjustified, use of omeprazole, and with its prolonged use.
Downloads
Metrics
References
Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol.
;46(2):93-114. DOI: http://dx.doi.org/10.1097/MCG.0b013e3182333820 DOI: https://doi.org/10.1097/MCG.0b013e3182333820
Micromedex® Truven Health Analytics. V.2.0. DRUGDEX System. The Healthcare Business of Thomson Reuters, 2015.
[acesso 8 Ago 2015]. Disponível em: http://www.micromedexsolutions.com/home/dispatch
Wolters Kluwer. Omeprazole: Drug Information. In: Up To Date. [acesso 10 Ago 2015]. Disponível em: http://www.uptodate.
com/contents/omeprazoledruginformation?source=search_result&search=omeprazole&selectedTitle=1%7E150
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência
Farmacêutica e Insumos Estratégicos. Uso Racional de Medicamentos: temas selecionados. Brasília: Ministério da Saúde;
Brasil. Ministério da Saúde. Relação Nacional de Medicamentos Essenciais: RENAME 2014. 9a ed. Brasília: Ministério da
Saúde; 2015.
World Health Organization. WHO Model List of Essential Medicines. [acesso 4 Ago 2015]. Disponível em: http://www.who.
int/selection_medicines/list/en/
Hoefler R, Leite BF. Segurança do uso contínuo de inibidores da bomba de prótons. Farmacoterapêutica. 2009;14(1-2):1-3.
Lima APV, Neto Filho MA. Efeitos em longo prazo de inibidores da bomba de prótons. Braz. J Surg Clin Res. 2013:5(3):45-9.
Caricol FC. Seguridad del omeprazol: ¿es adecuada la duración de los tratamientos? Farm Comunitarios. 2015;7(1):5-9. DOI: https://doi.org/10.5672/FC.2173-9218.(2015/Vol7).001.02
Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev
Clin Pharmacol. 2013;6(4):443-51. DOI: http://dx.doi.org/10.1586/17512433.2013.811206 DOI: https://doi.org/10.1586/17512433.2013.811206
García Rodríguez LA, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin
Gastroenterol Hepatol. 2007;5(12):1418-23. DOI: http://dx.doi.org/10.1016/j.cgh.2007.09.010 DOI: https://doi.org/10.1016/j.cgh.2007.09.010
Souza IKF, Silva AL, Araújo Júnior A, Santos FCB, Mendonça BPCK. Análise qualitativa das alterações anatomopatológicas
na mucosa gástrica decorrentes da terapêutica prolongada com inibidores da bomba de prótons: estudos experimentais
x estudos clínicos. Arq Bras Cir Dig. 2013;26(4):328-34. DOI: http://dx.doi.org/10.1590/S0102-67202013000400015 DOI: https://doi.org/10.1590/S0102-67202013000400015
Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJ, et al. Effects of long-term administration of
omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop. 2015;50(2):232-8. DOI: DOI: https://doi.org/10.1016/j.rboe.2015.03.002
http://dx.doi.org/10.1016/j.rbo.2014.05.012 DOI: https://doi.org/10.1016/j.rbo.2014.05.012
Menegassi VS, Czeczko LEA, Czekzo LSG, Ioshi SO, Pisani JC, Ramos Junior O. Prevalência de alterações proliferativas
gástricas em pacientes com uso crônico de inibidores de bomba de prótons. Arq Bras Cir Dig. 2010;23(3):145-9. DOI:
http://dx.doi.org/10.1590/S0102-67202010000300003 DOI: https://doi.org/10.1590/S0102-67202010000300003
Ameijeiras AH, González BC, Zúñiga VL. Prevalencia de prescripción-indicación de protectores gástricos en pacientes
hospitalizados. Gac Sanit. 2007;21(5):412-5. DOI: http://dx.doi.org/10.1157/13110449 DOI: https://doi.org/10.1157/13110449
Palazón EM, Moreno CB. Inhibidores de la bomba de protones, ¿la protección mal entendida? FMC Form Med Contin
Aten Prim. 2011;18(5):243-5.
Centro de Informação sobre Medicamentos. Uso Racional de omeprazol. Alerta terapêutico – Junho 2009. [acesso 10 Ago
. Disponível em: http://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/arquivos/assistenciafarmaceutica/omeprazol.pdf
Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C. Interventions to improve the appropriate use of
polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165.
Schroeter G, Chaves LL, Engroff P, Faggiani FT, DE Carli GA, Morrone FB. Estudo de utilização de anti-ulcerosos na
população Idosa de Porto Alegre, RS, Brasil. Rev HCPA. 2008;28(2):89-95.
López-Dóriga Bonnardeaux P, Neira Álvarez M, Mansilla Laguía S. Inhibidores de la bomba de protones: estudio de
prescripción en una Unidad de Recuperación Funcional. Rev Esp Geriatr Gerontol. 2013;48(6):269-71. DOI: http://dx.doi. DOI: https://doi.org/10.1016/j.regg.2013.07.004
org/10.1016/j.regg.2013.07.004
Rozenfeld S. Prevalência, fatores associados e mau uso de medicamentos entre os idosos: uma revisão. Cad Saúde
Pública. 2003;19(3):717-24. DOI: http://dx.doi.org/10.1590/S0102-311X2003000300004 DOI: https://doi.org/10.1590/S0102-311X2003000300004
Moraes-Filho JP, Chinzon D, Eisig JN, Hashimoto CL, Zaterka S. Prevalence of heartburn and gastroesophageal reflux
disease in the urban Brazilian population. Arq Gastroenterol. 2005;42(2):122-7. PMID: 16127569 DOI: http://dx.doi. DOI: https://doi.org/10.1590/S0004-28032005000200011
org/10.1590/S0004-28032005000200011
Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43(1):161-73. PMID: 24503366 DOI: http:// DOI: https://doi.org/10.1016/j.gtc.2013.11.009
dx.doi.org/10.1016/j.gtc.2013.11.009
Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a
systematic review. Fam Pract. 2014;31(6):625-30. DOI: http://dx.doi.org/10.1093/fampra/cmu050 DOI: https://doi.org/10.1093/fampra/cmu050
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.